首页> 外文期刊>Urologic oncology >Predictors of biochemical recurrence after primary focal cryosurgery (hemiablation) for localized prostate cancer: A multi-institutional analytic comparison of Phoenix and Stuttgart criteria
【24h】

Predictors of biochemical recurrence after primary focal cryosurgery (hemiablation) for localized prostate cancer: A multi-institutional analytic comparison of Phoenix and Stuttgart criteria

机译:局部前列腺癌原发性局灶性冷冻蛋白(半粘液)后生化复发预测因素:凤凰与斯图加特标准的多制度分析比较

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract Background The Phoenix definition (PD) and Stuttgart definition (SD) designed to determine biochemical recurrence (BCR) in patients with postradiotherapy and high-intensity focused ultrasound organ-confined prostate cancer are being applied to follow patients after cryosurgery. We sought to identify predictors of BCR using the PD and SD criteria in patients who underwent primary focal cryosurgery (PFC). Materials and methods We performed a retrospective review of patients who underwent PFC (hemiablation) at 2 referral centers from 2000 to 2014. Patients were followed up with serial prostate-specific antigen (PSA). PSA levels, pre- and post-PFC biopsy, Gleason scores, number of positive cores, and BCR (PD = [PSA nadir+2ng/ml]; SD = [PSA nadir+1.2ng/ml]) were recorded. Patients who experienced BCR were biopsied, monitored carefully or treated at the discretion of the treating urologist. Cox regression and survival analyses were performed to assess time to BCR using PD and SD. Results A total of 163 patients were included with a median follow-up of 36.6 (interquartile range: 18.9–56.4) months. In all, 64 (39.5%) and 98 (60.5%) experienced BCR based on PD and SD, respectively. On multivariable Cox regression, the number of positive pre-PFC biopsy cores was an independent predictor of both PD (hazard ratio [HR] = 1.4, P = 0.001) and SD (HR = 1.3, P = 0.006) BCRs. Post-PFC PSA nadir was an independent predictor of BCR using the PD (HR = 2.2, P = 0.024) but not SD (HR = 1.4, P = 0.181). Survival analysis demonstrated a 3-year BCR-free survival rate of 56% and 36% for PD and SD, respectively. Of those biopsied after BCR, 14/26 (53.8%) using the PD and 18/35 (51.4%) using the SD were found to have residual/recurrent cancer. Of those with prostate cancer on post-PFC biopsy, 57.1% of those with BCR by the PD and 66.7% of those with BCR by the SD were found to have a Gleason score ≥7. Conclusion Both the PD and the SD may be used to determine BCR in post-PFC patients. However, the ideal definition of BCR after PFC remains to be elucidated. Highlights ? Phoenix and Stuttgart criteria for determining biochemical recurrence in post–primary focal cryosurgery of the prostate over estimates disease recurrence. ? The higher the number of pre–primary focal cryosurgery–positive cores, the greater the chances of biochemical recurrence as defined by the Phoenix and Stuttgart criteria. ? Patients suspected of biochemical recurrence by Phoenix and Stuttgart criteria may harbor clinically significant prostate cancer upon biopsy. ]]>
机译:摘要背景普通植物定义(PD)和斯图加特定义(SD)旨在测定生物化学再次发生(BCR)的患者患者和高强度聚焦的超声器官密闭的前列腺癌正在追踪冷冻疗法后患者。我们试图使用PD和SD标准识别BCR的预测因素,所述PD和SD标准接受初级局灶性冷冻疗法(PFC)。材料和方法我们对2000年至2014年的2个转诊中心接受了PFC(半纤维)的患者进行了回顾性评论。患者随访连续前列腺特异性抗原(PSA)。 PSA水平,PFC后和PFC后活检,GLEASON评分,阳性核和BCR(PD = [PSA Nadir + 2ng / mL]; SD =Φ[PSA Nadir + 1.2ng / ml])被记录。经历BCR的患者是活检,仔细监测或由治疗泌尿科医师的判断进行治疗。使用Pd和Sd进行Cox回归和存活分析以评估BCR的时间。结果共有163名患者,中位随访36.6(四分位数范围:18.9-56.4)个月。总共64(39.5%)和98(60.5%)分别经历了基于PD和SD的BCR。在多变量Cox回归中,阳性Pre-PFC活检核的数量是Pd(危害比[HR] = 1.4,P = 0.001)和SD(HR = 1.3,P = 0.006)BCR的独立预测因子。 PYC PSA Nadir是使用Pd(HR = 2.2,P = 0.024)的BCR的独立预测因子,但不是SD(HR = 1.4,P = 0.181)。存活分析分别证明了Pd和Sd的3年的BCR活存率为56%和36%。在BCR后的那些活检的中,发现使用SD使用Pd和18/35(51.4%)的14/26(53.8%)具有残留/复发性癌症。在PFC后前列腺癌的那些癌症的癌症,PD的57.1%的BCR和SD的66.7%的BCR的66.7%有一个gleason得分≥7。结论Pd和Sd都可用于确定PRE-PFC患者的BCR。然而,PFC后BCR的理想定义仍然被阐明。强调 ?凤凰和斯图加特确定前列腺后前局部局灶性冷冻蛋白的生化复发的标准估计疾病复发。还预先临床局灶性阳性阳性核的数量越高,凤凰和斯图加特标准所定义的生物化学复发的可能性越大。还涉嫌凤凰和斯图加特标准的生化复发的患者可能在活组织检查时含有临床显着的前列腺癌。 ]]>

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号